Bank of Montreal
NKTR icon

Bank of Montreal’s Nektar Therapeutics NKTR Stock Holding History

Bank of Montreal’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,633
Closed -$50.7K – 3661
2024
Q4 		$50.7K Hold
3,633
– – ﹤0.01% 3104
2024
Q3 		$63.8K Hold
3,633
– – ﹤0.01% 3362
2024
Q2 		$68.7K Hold
3,633
– – ﹤0.01% 3357
2024
Q1 		$51.2K Sell
3,633
-6,940
-66% -$72.7K ﹤0.01% 3444
2023
Q4 		$91.4K Buy
10,573
+9,673
+1,075% +$73.3K ﹤0.01% 3406
2023
Q3 		$9.81K Hold
900
– – ﹤0.01% 3627
2023
Q2 		$7.83K Sell
900
-1,747
-66% -$18.6K ﹤0.01% 3818
2023
Q1 		$28.7K Buy
2,647
+358
+16% +$10.8K ﹤0.01% 3468
2022
Q4 		$77.6K Sell
2,289
-1,083
-32% -$52.4K ﹤0.01% 3435
2022
Q3 		$168 Sell
3,372
-15,513
-82% -$923K ﹤0.01% 3275
2022
Q2 		$1.17K Buy
18,885
+14,294
+311% +$902K ﹤0.01% 2213
2022
Q1 		$384K Sell
4,591
-379
-8% -$56.1K ﹤0.01% 3027
2021
Q4 		$1.05M Buy
4,970
+2,731
+122% +$592K ﹤0.01% 1913
2021
Q3 		$632K Sell
2,239
-112
-5% -$26.9K ﹤0.01% 2746
2021
Q2 		$626K Buy
2,351
+621
+36% +$172K ﹤0.01% 2714
2021
Q1 		$499K Buy
1,730
+590
+52% +$184K ﹤0.01% 2643
2020
Q4 		$320K Buy
1,140
+164
+17% +$42.4K ﹤0.01% 2958
2020
Q3 		$251K Sell
976
-15
-2% -$4.72K ﹤0.01% 2638
2020
Q2 		$363K Buy
991
+502
+103% +$157K ﹤0.01% 2434
2020
Q1 		$125K Sell
489
-6,554
-93% -$2.03M ﹤0.01% 2511
2019
Q4 		$2.28M Sell
7,043
-3,007
-30% -$872K ﹤0.01% 1808
2019
Q3 		$2.75M Sell
10,050
-1,798
-15% -$659K ﹤0.01% 1480
2019
Q2 		$6.32M Buy
11,848
+1,278
+12% +$641K 0.01% 1102
2019
Q1 		$5.33M Sell
10,570
-4,133
-28% -$2.45M ﹤0.01% 1125
2018
Q4 		$7.25M Sell
14,703
-1,019
-6% -$615K 0.01% 910
2018
Q3 		$14.4M Buy
15,722
+6,556
+72% +$5.6M 0.01% 776
2018
Q2 		$6.71M Buy
9,166
+2,184
+31% +$2.52M 0.01% 1032
2018
Q1 		$11.1M Buy
6,982
+6,499
+1,346% +$8.37M 0.01% 818
2017
Q4 		$433K Sell
483
-45
-9% -$26.6K ﹤0.01% 2351
2017
Q3 		$190K Buy
528
+35
+7% +$10.9K ﹤0.01% 2694
2017
Q2 		$145K Sell
493
-53
-10% -$15.3K ﹤0.01% 2813
2017
Q1 		$192K Buy
546
+97
+22% +$21.8K ﹤0.01% 2495
2016
Q4 		$83K Buy
449
+23
+5% +$4.68K ﹤0.01% 2916
2016
Q3 		$110K Buy
426
+14
+3% +$3.6K ﹤0.01% 2724
2016
Q2 		$88K Sell
412
-93
-18% -$20.8K ﹤0.01% 2858
2016
Q1 		$104K Buy
505
+58
+13% +$11.1K ﹤0.01% 2779
2015
Q4 		$113K Buy
447
+179
+67% +$36.8K ﹤0.01% 2718
2015
Q3 		$44K Buy
+268
New +$47.4K ﹤0.01% 2972
2015
Q2 		– Sell
-1,162
Closed -$192K – 4053
2015
Q1 		$192K Sell
1,162
-120
-9% -$24.7K ﹤0.01% 2381
2014
Q4 		$298K Buy
+1,282
New +$274K ﹤0.01% 2304
2014
Q3 		– Sell
-213
Closed -$41K – 4273
2014
Q2 		$41K Buy
+213
New +$37.7K ﹤0.01% 3290

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Bank of Montreal's NKTR Position: Q1 2025 in Review

Bank of Montreal sold out of Nektar Therapeutics (NKTR) in Q1 2025, closing a stake of 3,633 shares — an estimated $50.7K sold.

Bank of Montreal first reported a position in NKTR in Q2 2014 and held it in 41 quarters. The position peaked at $14.4M in Q3 2018. 154 funds tracked by Wall St. Rank hold NKTR as of Q1 2025.

  • Bank of Montreal reported no remaining Nektar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bank of Montreal sold 3,633 Nektar Therapeutics shares in Q1 2025, an estimated $50.7K.
  • Bank of Montreal first reported a position in Nektar Therapeutics in Q2 2014 and held it in 41 quarters.
  • Bank of Montreal's Nektar Therapeutics position peaked at $14.4M in Q3 2018.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2025.

Based on Bank of Montreal's 13F filing for Q1 2025, filed 13 May 2025.